id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-E-1244-0006,FDA,FDA-2012-E-1244,"Determination of Regulatory Review Period for Purposes of Patent
Extension; MENHIBRIX",Notice,General Notice,2014-05-28T04:00:00Z,2014,5,2014-05-28T04:00:00Z,,2014-05-28T14:14:11Z,2014-12294,0,0,0900006481718c1b
FDA-2012-E-1244-0005,FDA,FDA-2012-E-1244,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2014-05-12T04:00:00Z,2014,5,2014-05-12T04:00:00Z,,2014-05-12T16:59:00Z,,0,0,09000064816f1b68
FDA-2012-E-1244-0004,FDA,FDA-2012-E-1244,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2014-04-08T04:00:00Z,2014,4,2014-04-08T04:00:00Z,,2014-04-09T01:49:32Z,,0,0,09000064816a9f69